百济神州：泽布替尼新剂型预计今年下半年在欧美获批

医药魔方2025-05-08

5月7日，百济神州发布2025Q1财报，其产品收入为79.85亿元，同比增长49.9%；公司营业总收入为80.48亿元，同比增长50.2%；2025年第一季度归属于母公司所有者的净利润为-0.95亿元。泽布替尼（百悦泽）2025Q1的全球销售额总计56.92亿元，同比增长63.7%。而根据阿斯利康财报，阿可替尼2025Q1的全球销售额为7.62亿美元（1美元=7.1829元人民币，约合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533917313?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-08 10:35","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533917313","market":"hk","top_or_hot":-1,"title":"百济神州：泽布替尼新剂型预计今年下半年在欧美获批","media":"医药魔方","content":"<div>\n<p>5月7日， 百济神州 发布2025Q1财报，其产品收入为79.85亿元，同比增长49.9%；公司营业总收入为80.48亿元，同比增长50.2%；2025年第一季度归属于母公司所有者的净利润为-0.95亿元。泽布替尼（百悦泽）2025Q1的全球销售额总计56.92亿元，同比增长63.7%。而根据阿斯利康财报，阿可替尼2025Q1的全球销售额为7.62亿美元（1美元=7.1829元人民币，约合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州：泽布替尼新剂型预计今年下半年在欧美获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州：泽布替尼新剂型预计今年下半年在欧美获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-08 10:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b><strong>医药魔方</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月7日， 百济神州 发布2025Q1财报，其产品收入为79.85亿元，同比增长49.9%；公司营业总收入为80.48亿元，同比增长50.2%；2025年第一季度归属于母公司所有者的净利润为-0.95亿元。泽布替尼（百悦泽）2025Q1的全球销售额总计56.92亿元，同比增长63.7%。而根据阿斯利康财报，阿可替尼2025Q1的全球销售额为7.62亿美元（1美元=7.1829元人民币，约合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0588546209.SGD","symbol_name":"Eastspring Investments - China Equity Fund AS SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","article_id":"2533917313","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533917313","pubTimestamp":1746671753,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"目前泽布替尼获批的剂型为胶囊。百济神州已计划对R/R MCL适应症的II期临床试验进行数据读出并有望针对该项适应症在2025年下半年递交全球加速上市申请。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1500":"做空集合股","06160":"百济神州","BK1161":"生物科技","BK1583":"高瓴概念","BK1588":"回港中概股","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","ONC":"百济神州","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"BeiGene: The new dosage form of zanubrutinib is expected to be approved in Europe and America in the second half of this year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9,"ONC":0.9,"06160":1},"content_text":"5月7日， 百济神州 发布2025Q1财报，其产品收入为79.85亿元，同比增长49.9%；公司营业总收入为80.48亿元，同比增长50.2%；2025年第一季度归属于母公司所有者的净利润为-0.95亿元。泽布替尼（百悦泽）2025Q1的全球销售额总计56.92亿元，同比增长63.7%。而根据阿斯利康财报，阿可替尼2025Q1的全球销售额为7.62亿美元（1美元=7.1829元人民币，约合54.73亿元），同比增长8%。具体来看，泽布替尼美国销售额总计40.41亿元，同比增长61.9%，主要得益于需求的增长，其中超过60%的季度环比增长来自于在慢性淋巴细胞白血病（CLL）适应症中使用的扩大，该产品在美国是CLL和所有其他已获批适应症新增患者治疗领域的领导者。欧洲销售额总计8.36亿元，同比增长75.4%。中国销售额总计5.90亿元，同比增长43.1%。此外，百济神州透露预计将于2025 年下半年取得FDA和EC对泽布替尼片剂新剂型上市申请的批准。目前泽布替尼获批的剂型为胶囊。2025年第一季度，替雷利珠单抗（百泽安）的销售额总计12.45亿元，同比增长19.3%。替雷利珠单抗已在中国PD-1市场取得领先的市场份额。百济神州预计将于2025年上半年取得EC对替雷利珠单抗用于治疗新辅助/辅助非小细胞肺癌的批准，将于2025年下半年取得EC对替雷利珠单抗用于一线治疗鼻咽癌的批准，并计划于2025年下半年启动替雷利珠单抗皮下制剂III期试验。新药开发进展方面，百济神州已基于Bcl-2抑制剂索托克拉 BGB-11417-202 试验在中国申报上市，用于治疗R/R CLL患者。百济神州已计划对R/R MCL适应症的II期临床试验进行数据读出并有望针对该项适应症在2025年下半年递交全球加速上市申请。BTK CDAC药物BGB-16673用于治疗R/R CLL患者的潜在注册性II期临床试验继续入组患者，预计将于2026 年读出数据。目前，百济神州内部全球研发（包括临床运营及开发）团队拥有约3,700人，并任命了Marcello Damiani 为公司首席技术官。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533917313","isCrawlerRequest":true}